Cosmos Health Inc. has signed an agreement to deploy an Artificial Intelligence (AI)-powered call center at its wholly owned subsidiary, CosmoFarm S.A., to optimize order intake and customer communications. This strategic move aims to enhance process optimization, cost efficiencies, and responsiveness as the subsidiary scales its operations. The new system will support inbound and outbound calls through a multilingual voice assistant, intelligent call handling, and real-time reporting, building upon the company's broader AI strategy announced in April 2026.

Expansion and Automation Investments

The deployment of the AI-powered call center is the latest step in Cosmos Health's ongoing integration of AI across its front-end and back-end operations. The company believes that AI-driven optimization may reduce specific operating expenses by up to 30%, depending on the process and level of automation. This initiative complements CosmoFarm's existing automated infrastructure, including ROWA and SSI SCHÄFER A-frame robotic systems, which have already driven improvements in operational efficiency and profitability per customer.

Financial Performance and Growth

CosmoFarm S.A. recently delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million. The subsidiary added more than 80 new pharmacies to its distribution network during the period, solidifying its position as a leading pharmaceutical wholesaler in the greater Athens area. To support this accelerating growth, Cosmos Health is increasing capital expenditure at CosmoFarm, investing in new robotic automation and expanded facility capacity.

Key Performance Indicators

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated that deploying an AI-powered call center is a natural next step in the company's AI strategy, using technology to drive process optimization and improved customer experience. He noted that this is expected to deliver meaningful benefits across operations, particularly within CosmoFarm, where record growth and a rapidly expanding customer base make intelligent automation increasingly valuable. Siokas emphasized that the company is building a more efficient, scalable, and competitive business by integrating AI across its operations.

Cosmos Health Inc. has secured a cumulative orderbook of over 25 million units through its wholly owned subsidiary Cana Laboratories S.A., positioning the contract manufacturing division to generate over $10 million in recurring annual profit at full capacity. The agreements span multiple partners and nine therapeutic categories, with contract terms extending up to 10 years, providing long-term cash flow visibility and reducing dependence on any single product or partner.

Cana operates a 54,000 sq. ft., EU-GMP-licensed, EMA-certified facility in Athens. The company has invested approximately $5.5 million in upgrading the facility, including the installation of a new ACG capsule-filling line, to expand its capabilities. The orderbook includes diverse formats such as vials, packs, bottles, capsules, and pessaries, covering central nervous system, musculoskeletal, dermatological, vitamin, anti-inflammatory, oncology-support, women’s health, antiseptic, and wellness categories.

Contract Manufacturing Orderbook

The following table details the key agreements secured by Cana Laboratories:

Strategic Impact

Cosmos Health views contract manufacturing as a high-margin, recurring-revenue segment central to its vertically integrated model. By leveraging its EU-licensed facility to serve third-party partners, the company aims to maximize utilization, spread fixed costs, and generate incremental revenue while maintaining control over the quality and supply of its own proprietary brands. With current agreements using only a portion of available capacity, the company continues to pursue additional contracts and evaluate further expansion.